Global Organ Transplant Rejection Medication Market Size study & Forecast, by Drug Class (Antibodies, Antimetabolites, Calcineurin Inhibitors, mTOR Inhibitors, Steroids), by Transplant Type (Kidney, Liver, Heart, Lung, Pancreas, Others), by Distribution C

Global Organ Transplant Rejection Medication Market Size study & Forecast, by Drug Class (Antibodies, Antimetabolites, Calcineurin Inhibitors, mTOR Inhibitors, Steroids), by Transplant Type (Kidney, Liver, Heart, Lung, Pancreas, Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

Global Organ Transplant Rejection Medication Market is valued at approximately USD 4.9 billion in 2022 and is anticipated to grow with a growth rate of more than 3.9% over the forecast period 2023-2030. Organ transplantation is a surgical procedure in which tissue, or an organ is transferred from one person's body to another person’s body. Organ transplant rejection medication is used to prevent organ rejection in transplant recipients. The rising incidence of chronic disease and the increased incidence of organ failure are the key factors responsible for the market growth of the Organ Transplant Rejection Medication Market over the forecast period.

According to the Health Resources and Services Administration. In 2022, in the U.S., more than 42,887 organ transplants were performed and it's an increase of 3.7% over 2021. Also, according to the Department of Health & Human Services, in Mar 2023, approximately 104,234 patients across the globe were waiting to receive organs for transplant. Thus, the rising incidence of chronic disease and the increased incidence of organ failure are fueling the market demand across the globe. Also, advancements in technology, such as new surgical techniques and immunosuppressive drugs and a rise in the number of organ donors accelerate market growth. Moreover, increased awareness about the benefits of organ transplantation in an aging population and an increase in funding for research and development are anticipated to create lucrative growth opportunities for the market. However, the high cost and complex procedures stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Organ Transplant Rejection Medication Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in terms of revenue owing to factors such as the rising incidence of chronic disease, favorable reimbursement policies, technological advancement and the presence of advanced healthcare infrastructure create market growth in this region. Asia-Pacific is the fastest-growing region due to increasing incidence of chronic diseases, rising healthcare expenditure, rise in affordability and increased awareness about organ rejection medications in the region.

Major market player included in this report are:
Pfizer, Inc.
Astellas Pharma Global Development, Inc.
F, Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
AbbVie Inc.
Viatris, Inc.
Hikma Pharmaceuticals plc.
Teva Pharmaceutical Industries Ltd
Cadila Healthcare Limited

Recent Developments in the Market:
In August 2022, Strides gained USFDA certification for their Cyclosporine Softgel Capsule. Strides strengthened its market position by adding Cyclosporine Softgel capsules, Tacrolimus capsules and an immunosuppressive medicine line for the US market.

Global Organ Transplant Rejection Medication Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Class, Transplant Type, Distribution channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Antibodies
Antimetabolites
Calcineurin Inhibitors
mTOR Inhibitors
Steroids

By Transplant Type:
Kidney
Liver
Heart
Lung
Pancreas
Others

By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Pfizer, Inc.
Astellas Pharma Global Development, Inc.
F, Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
AbbVie Inc.
Viatris, Inc.
Hikma Pharmaceuticals plc.
Teva Pharmaceutical Industries Ltd
Cadila Healthcare Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.